ImmunityBio Secures Key Partnerships for European and Middle Eastern Oncology Launch

ImmunityBio signs major distribution deals in Europe and MENA for its bladder & lung cancer therapy, following approvals in 33 countries based on strong clinical data.

ImmunityBio has taken decisive steps to bring its innovative cancer therapy to international markets, announcing two major distribution agreements. This strategic expansion into Europe and the Middle East comes on the heels of significant regulatory approvals for the treatment of bladder cancer and non-small cell lung cancer.

Clinical Data Underpins Global Approvals

The therapy's regulatory pathway is supported by clinical trial results demonstrating a complete response rate of 71%, with a median response duration of 26.6 months. This data has facilitated authorizations across 33 countries within four primary jurisdictions: the United States, the United Kingdom, Saudi Arabia, and the European Union. The medical need is substantial; within the EU and UK alone, approximately 157,000 cases of non-muscle invasive bladder cancer are diagnosed annually, with carcinoma in situ present in 10 to 20% of patients.

In the U.S., the company recently submitted a filing to the FDA concerning papillary disease. A separate clinical study for treatment-naïve patients is nearing full recruitment.

European Rollout Led by Accord Healthcare

For commercialization across the European Union, United Kingdom, and European Free Trade Association countries, ImmunityBio has entered a partnership with Accord Healthcare. The agreement provides access to an 85-member specialty sales force tasked with covering 30 European nations. This move follows a conditional marketing authorization granted by the European Commission for the treatment of adult patients with carcinoma in situ of the bladder who have failed prior standard therapy.

To facilitate its European operations, the biotech firm has established an Irish subsidiary headquartered in Dublin.

Accelerated Access in MENA Region

In a parallel development for the Middle East and North Africa (MENA), ImmunityBio has appointed Biopharma and Cigalah Healthcare as its distributors. The partnership covers Saudi Arabia and the broader regional market, with plans to make the approved therapy physically available within 60 days.

The Saudi Food and Drug Authority had previously granted accelerated approval for two indications: bladder cancer and metastatic non-small cell lung cancer. ImmunityBio has also formed a dedicated Saudi Arabian subsidiary to manage regional activities. Furthermore, discussions are currently underway in the United Arab Emirates and Saudi Arabia regarding potential approvals for additional tumor types.

Market Activity and Legal Review

Trading activity saw more than 40 million shares change hands on February 20, with the stock closing at a price of $8.74. Concurrently, the law firm Pomerantz LLP announced it is examining certain prior communications from January related to clinical trials. The company's next financial report is scheduled for release on March 2.